Open AccessGenetically Engineered Mouse Models of Pancreatic Cancer: The KPC Model ( LSL‐Kras G12D/+ ;LSL‐Trp53 R172H/+ ;Pdx‐1‐Cre ), Its Variants, and Their Application in Immuno‐oncology Drug Discovery
Author(s) -
Lee Jae W.,
Komar Chad A.,
Bengsch Fee,
Graham Kathleen,
Beatty Gregory L.
Publication year - 2016
Publication title -
current protocols in pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.893
H-Index - 26
eISSN - 1934-8290
pISSN - 1934-8282
DOI - 10.1002/cpph.2
Subject(s) - pancreatic cancer , immunotherapy , kras , cancer , cancer research , genetically engineered , disease , drug development , biology , medicine , computational biology , oncology , drug , gene , genetics , pharmacology , colorectal cancer
Pancreatic ductal adenocarcinoma (PDAC) ranks fourth among cancer‐related deaths in the United States. For patients with unresectable disease, treatment options are limited and lack curative potential. Preclinical mouse models of PDAC that recapitulate the biology of human pancreatic cancer offer an opportunity for the rational development of novel treatment approaches that may improve patient outcomes. With the recent success of immunotherapy for subsets of patients with solid malignancies, interest is mounting in the possible use of immunotherapy for the treatment of PDAC. Considered in this unit is the value of genetic mouse models for characterizing the immunobiology of PDAC and for investigating novel immunotherapeutics. Several variants of these models are described, all of which may be used in drug development and for providing information on unique aspects of disease biology and therapeutic responsiveness. © 2016 by John Wiley & Sons, Inc.